Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas
暂无分享,去创建一个
[1] F. Motoi,et al. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection , 2022, Journal of hepato-biliary-pancreatic sciences.
[2] Angelika M. R. Kestler,et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) - a randomized phase II trial of the AIO pancreatic cancer group. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] G. Webersinke,et al. Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer , 2022, Frontiers in Oncology.
[4] M. Senthil,et al. Circulating Tumor DNA is Unreliable to Detect Somatic Gene Alterations in Gastrointestinal Peritoneal Carcinomatosis , 2022, Annals of Surgical Oncology.
[5] W. Hwang,et al. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma. , 2022, JCO precision oncology.
[6] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[7] P. Laurent-Puig,et al. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials , 2021, British Journal of Cancer.
[8] F. Motoi,et al. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases , 2021, Annals of Surgical Oncology.
[9] Ann M. Miller,et al. Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies , 2020, Annals of Surgical Oncology.
[10] L. Buscail,et al. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer , 2020, Nature Reviews Gastroenterology & Hepatology.
[11] W. Roth,et al. Liquid Biopsy im kolorektalen Karzinom , 2019, Der Pathologe.
[12] N. Hartmann,et al. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics]. , 2019, Der Pathologe.
[13] J. Nuyttens,et al. Postoperative surveillance of pancreatic cancer patients. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[14] J. Cameron,et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[15] Thierry Lecomte,et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.
[16] R. Kurzrock,et al. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival , 2018, Annals of Surgical Oncology.
[17] E. Sabo,et al. Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. , 2018, The oncologist.
[18] Xinhui Fang,et al. Liquid biopsy in colorectal cancer , 2018 .
[19] B. Dörken,et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Cameron,et al. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma , 2017, Annals of surgery.
[21] S. Horiguchi,et al. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[22] E. Hiyama,et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer , 2016, British Journal of Cancer.
[23] A. Parikh,et al. Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence? , 2016, Journal of the American College of Surgeons.
[24] B. Erickson,et al. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. , 2016, Surgery.
[25] S. Stein,et al. Circulating Cell-Free Tumour DNA in the Management of Cancer , 2015, International journal of molecular sciences.
[26] M. Kanda,et al. Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. , 2014, Hepato-gastroenterology.
[27] K. Jung,et al. Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[28] Rochelle L. Garcia,et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. , 2005, American journal of obstetrics and gynecology.
[29] S. Kitano,et al. Factors Predicting Recurrence After Resection of Pancreatic Ductal Carcinoma , 2005, Pancreas.
[30] M. Stroun,et al. Isolation and characterization of DNA from the plasma of cancer patients. , 1987, European journal of cancer & clinical oncology.
[31] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.